Novotech report explores how in-vivo CAR-T could transform cell therapy access and costs
A new whitepaper from Novotech has outlined how in-vivo CAR-T therapies are gaining momentum and could help overcome some of the cost and logistical barriers that have so far limited patient access to cell therapy.
Titled In-Vivo CAR Therapies – Global Research and Development Landscape (2025), the report explores the potential for this emerging technology to expand access to treatment across oncology, autoimmune diseases and other complex indications.
Unlike traditional ex-vivo CAR-T therapies, which involve removing a patient’s T cells, modifying them in a lab, and then reinfusing them, in-vivo CAR-T uses gene delivery methods to engineer T cells directly inside the patient’s body. Delivery technologies include viral vectors, lipid nanoparticles (LNPs), and mRNA platforms.
According to the report, these advances could help make CAR-T therapies faster to produce, more scalable and easier to access, with potential off-the-shelf applications. This could reduce costs and simplify patient logistics in ways that have not been possible with ex-vivo approaches.
The report also highlights that in-vivo CAR-T platforms are now being investigated not only for blood cancers but also for solid tumours, autoimmune diseases and fibrosis—areas where traditional CAR-T approaches have had limited success.
The report includes:
An overview of the evolution of CAR platforms and delivery technologies.
A review of the global clinical pipeline of in-vivo CAR-T assets.
Advances in LNP and viral vector strategies.
Commercial and regulatory factors that may influence future adoption.
Opportunities beyond oncology, including applications in autoimmune diseases and fibrotic disorders.
The company said it has supported the world’s first in-vivo CAR trial and has completed more than 100 advanced therapy studies, including gene therapies, gene-modified cell therapies and mRNA products.
A spokesperson for Novotech said: “As delivery systems improve, the in-vivo approach could help democratise access to cell therapies, while opening new the
